ERBB2 and ovarian cancer: In our ovarian cancer xenograft model, the intratumoral injection of HER2-CD3-Fc mRNA-LNPs triggered a potent antitumor effect and completely eliminated the HER2-positive A1847 tumors without showing any signs of toxic effects.